Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

The UCL–Lancet Commission on Migration and Health: the health of a world on the move


Executive Summary
With one billion people on the move or having moved in 2018, migration is a global reality. International migration has increased to 258 million, and the numbers of refugees and people displaced by conflict, natural disasters, and climate change are at their highest levels: 22 and 40 million, respectively. Despite negative political narratives, migration is not overwhelming high-income countries—instead, it takes place mostly between low-income and middle-income countries and most people are migrating for work. By and large, migration is a positive and diverse experience. But migration has also become a political lightning rod. 
The UCL–Lancet Commission on Migration and Health steps into this political debate to provide evidence for cooperation and action on what is one of the most pressing issues of the 21st century. The Commission’s foundation is that migration and health are inextricably linked—and key to sustainable development. It provides a framework of migration as a dynamic process, providing evidence of the multiple factors that could be beneficial or detrimental to individuals and systems along the migration journey—at origin, transit, destination, and return. It documents the devastating impacts of forced migration, especially on girls and women, but also the overall benefits to the health of individuals and populations that migration generates. It lays out a research agenda to better ensure the health of migrants. Using the lens of health the Commission shows that migration policies can be both ethical and feasible—calling for governments, international agencies, and professionals to promote health in global mobility.

Read More

Comments
Migration and health: human rights in the era of populism
Walid Ammar
The Lancet

"
Historically, the overall contribution of migrants to the economy and wealth of hosting countries has exceeded their costs. Migration helps address labour market imbalances, and migrants contribute more in taxes and social contributions than they receive in benefits. 
1 
However, increasing opposition to migration is expressed in political rhetoric and social media. Xenophobia and racism are galvanised by populist discourse that serves domestic political interests. A climate of intolerance facilitates the passing of discriminatory laws and the introduction of measures against migrants that contradict fundamental human rights. Additionally, public misinformation campaigns and the diffusion of fake news through social media make public opinion more receptive to extreme actions such as forced expulsions and building walls between peoples. The UCL– Lancet Commission on Migration and Health 
2 
makes a strong case for action to respond to the health needs of migrants while maximising the benefit from migration. The Commission provides evidence that discredits those who promote intolerance and shows that mortality is, on average, lower among migrants than people in host countries."

Link to the The Lancet Commission on Migration and Health
    1
    ...
ATC Name B/G ↑ Ingredients Dosage Form Price
G04CA53 VESOMNI B Tamsulosin HCl - 0.4mg, Solifenacin succinate - 6mg Tablet, modified release 4,491,122 L.L
S01LA09 VABYSMO B Faricimab - 6mg/0.05ml 6mg/0.05ml Injectable solution 54,991,170 L.L
D11AF VERRUMAL B Fluorouracil - 0.5g/100g, Salicylic acid - 10g/100g Solution 529,474 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 10mg 10mg Tablet, film coated 753,896 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 10mg 10mg Tablet, film coated 753,896 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 20mg 20mg Tablet, film coated 954,128 L.L
S02CA02 VIOCORTENE B Clioquinol - 10mg/ml, Flumetasone pivalate - 0.2mg/ml Drops 568,253 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 20mg 20mg Tablet, film coated 954,128 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 40mg 40mg Tablet, film coated 1,032,071 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 40mg 40mg Tablet, film coated 1,032,071 L.L
A11BA VITALIPID N INFANT B Vitamin A - 230IU/ml, Vitamin D2 - 40IU/ml, Vitamin E - 0.7IU/ml, Vitamin K1 - 20mcg/ml Injectable concentrate for solution 2,448,481 L.L
C10AX06 VASCEPA B Eicosapentaenoic acid (Ethyl ester) - 1g 1g Capsule 21,464,912 L.L
L01BC07 VIDAZA B Azacitidine - 100mg 100mg Injectable lyophilised powder 15,158,791 L.L
B03AC VENOFER I.V. B Iron (sucrose) - 100mg/5ml 100mg/5ml Injectable concentrated solution 3,594,779 L.L
N07XX08 VYNDAMAX B Tafamidis - 61mg 61mg Capsule 784,020,041 L.L
J02AC03 VFEND B Voriconazole - 200mg 200mg Tablet, film coated 51,904,550 L.L
J02AC03 V-FEND B Voriconazole - 200mg 200mg Injectable powder for solution 8,078,564 L.L
L01XG01 VELCADE B Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder for solution 23,616,000 L.L
N05BA01 VALIUM B Diazepam - 5mg 5mg Tablet, scored 200,233 L.L
P02CA01 VERMOX B Mebendazole - 100mg/5ml 100mg/5ml Suspension 196,201 L.L
P02CA01 VERMOX B Mebendazole - 100mg/5ml 100mg/5ml Suspension 196,201 L.L
P02CA01 VERMOX B Mebendazole - 500mg 500mg Tablet 106,164 L.L
M01AB05 VOLTFAST B Diclofenac potassium - 50mg 50mg Powder for solution 165,293 L.L
P02CA01 VERMOX B Mebendazole - 500mg 500mg Tablet 106,164 L.L
M01AB05 VOLTFAST B Diclofenac potassium - 50mg 50mg Powder for solution 545,600 L.L
P02CA01 VERMOX B Mebendazole - 100mg 100mg Tablet 129,009 L.L
C09DA08 VOTUM PLUS B Olmesartan medoxomil - 40mg, Hydrochlorothiazide - 25mg Tablet, film coated 933,971 L.L
P02CA01 VERMOX B Mebendazole - 100mg 100mg Tablet 129,009 L.L
C09DA08 VOTUM PLUS B Olmesartan medoxomil - 40mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 933,971 L.L
C09DA08 VOTUM PLUS B Olmesartan medoxomil - 20mg, Hydrochlorothiazide - 25mg Tablet, film coated 900,374 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025